GXO Logistics Inc vs McKesson Corporation — how do they compare? GXO Logistics Inc trades at $46.64 (market cap $5.32B), while McKesson Corporation trades at $937.1 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 20.4× GXO Logistics Inc's market cap, and McKesson Corporation pays a 0.4% dividend while GXO Logistics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GXO Logistics Inc for 28 Days and McKesson Corporation for 74 Days on average.
| GXO | MCK | |
|---|---|---|
Market Cap | $5.32B | $108.46B |
Volume | 1,255,816 | 712,607 |
Sector | Industrials | Health |
52-Week High | $65.59 | $995.69 |
52-Week Low | $44.17 | $725.17 |
Typical Hold Time | 28 Days | 74 Days |
Enterprise Value | $10.67B | $115.00B |
Dividend Yield | — | 0.4% |
Signals from Pluang's Aura AI — not financial advice
GXO trades at $46.47, up 1.04% with neutral technical indicators and strong analyst support. The company shows improving fundamentals with Q2 2026 revenue of $3.4 billion (up 4% YoY) and three consecutive earnings beats. Recent strategic partnerships with Columbia Sportswear and technology investments in labor management systems position GXO for operational efficiency gains. The stock trades at a P/E of 41.03 and P/S of 0.39, reflecting growth expectations amid modest current profitability.
GXO presents a compelling growth story with 88.9% analyst buy ratings and a $66.67 consensus price target (43% upside). However, margin compression remains a concern as new business wins show lower incremental profitability. The company's expansion in aerospace/defense and European logistics markets provides growth catalysts, but investors should monitor execution on the 6% EBIT margin target and supply chain industry headwinds.
McKesson Corporation (MCK) trades at $937.98, up 3.04% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent positive developments include the CVS Health partnership extension through 2032 and raised full-year guidance. Revenue growth remains robust at $359.05 billion for 2025, though net margins are thin at 1.12%.
The outlook remains positive with 81% analyst buy ratings and a $956.43 consensus target. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. Strong cash flow generation ($6.09B operating cash flow) supports the dividend and growth initiatives, while technical indicators show the stock testing resistance near $938.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.
Read more on GXO →McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →